Overview

Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC

Status:
Completed
Trial end date:
2021-07-30
Target enrollment:
Participant gender:
Summary
Previous studies have shown that irreversible electroporation (IRE) preoperative induction chemotherapy or adjuvant chemotherapy after IRE can reduce the local recurrence rate of locally advanced pancreatic cancer (LAPC) and benefit the survival of patients. According to the technical principle of electroporation therapy (EPT), when the cell membrane is electroporated, the resistance of cell membrane decreases instantaneously, which promotes the drug to enter tumor cells and significantly increases its cytotoxicity and killing effect on tumor tissue. The purpose of study is to evaluate the safety and effectiveness of simultaneous gemcitabine administration and IRE for treating LAPC. In order to provide new ideas for the treatment of LAPC.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Fuda Cancer Hospital, Guangzhou
Treatments:
Gemcitabine